Optic disk melanocytoma associated with polypoidal choroidal vasculopathy lesions, after combination treatment of photodynamic therapy and intavitreal aflibercept (Eylea), a case report

Alexandros Rouvas¹*, Nikolaos S Gouliopoulos¹, Marilita M Moschos² and Panagiotis Theodossiadis¹

Abstract

Background: We report a rare case of a woman with optic disk melanocytoma (ODMC) in conjunction with polypoidal choroidal vasculopathy (PCV). We also present, for the first time in literature, the clinical and morphological outcomes of the applied treatment, consisting of a session of photodynamic therapy (PDT) and three monthly intravitreal aflibercept injections.

Case presentation: An 83-year-old Greek woman, complaining for visual decline at her left eye, referred to our department and was diagnosed with ODMC associated with PCV. At presentation, best corrected visual acuity (BCVA) was 2/10, fundus examination revealed a pigmented lesion covering partially the optic nerve head and extending into the peripapillary choroid and retina, while hard exudates were observed temporal to it. Blocked hypofluorescence in the area covered by the lesion and diffuse hyperfluorescence at its temporal rim were shown by fluorescein angiography (FA). Indocyanine green angiography (ICGA) identified 3 hyperfluorescent polypoidal lesions arising from the choroidal vasculature. Optical coherence tomography (OCT) revealed subretinal fluid and retinal pigment epithelium detachment (RPE) at the region corresponding to polyps. The treatment included a PDT session combined with 3 monthly intravitreal aflibercept injections. Three months since the treatment initiation, new BCVA was 5/10, ICGA demonstrated total polyps occlusion, while OCT detected RPE detachment without subretinal fluid. Ten months later, ODMC was stable, BCVA rose to 7/10, no polyps were present, and total resolution of RPE detachment was achieved.

Conclusions: This is the first case report of PCV coexisting with ODMC, presenting both ICGA and OCT findings, and the applied treatment and its outcomes. Furthermore, we demonstrated that PDT combined with intravitreal aflibercept injections seems to be a promising treatment for PCV.

Keywords: Polypoidal choroidal vasculopathy, Optic disc melanocytoma, Aflibercept, Photodynamic therapy
Background
Optic disc melanocytoma (ODMC) is a rare ophthalmic tumor arising from melanocytes, and is considered to be a variant of the melanocytic nevus [1]. ODMC is a benign and deeply pigmented lesion, which obscures partially or completely the optic disc, extending frequently into the adjacent retina and/or choroid [1, 2]. Its pathogenesis is unknown, being either a congenital or an acquired clinical entity. Histologically, melanocytoma comprises round or oval and intensely pigmented nevus cells with benign features (abundant cytoplasm, small nuclei, and inconspicuous nucleoli) [2]. ODMC is usually unilateral and diagnosed in middle-aged adults. It is slightly more common in women, while almost 67% of cases are regarding white people [3]. ODMC is usually asymptomatic, however approximately 25% of the patients suffer by mild or severe visual deterioration, due to mild retinal exudation (involving the fovea) or neuroretinitis from tumor necrosis [1, 3, 4].

Polypoidal choroidal vasculopathy (PCV), first described by Yannuzzi et al. [5], is a clinical entity of un- }

Fifteen minutes after the infusion of verteporfin (dose of 6 mg/m² body surface area), its irradiation was performed according to the standard TAP guidelines [12]. Monthly intravitreal aflibercept injections. PDT was performed in combination with 3 monthly intravitreal aflibercept injections. PDT was performed according to the standard TAP guidelines [12]. Fifteen minutes after the infusion of verteporfin (dose of 6 mg/m² body surface area), its irradiation was performed using an ocular photoactivation diode and a laser-linked slit lamp. The treatment spot diameter, based on the ICGA findings, was approximately 1500 μm (Fig. 4) and it was targeted against the polyps and not the surrounding branching vascular network. The intravitreal injections of 2.0 mg aflibercept (Eylea, Bayer Healthcare, Germany), were performed under standard sterile conditions, while topical antibiotics were applied 4 times per day for 2 days after the injection.

PDT session was performed 7 days after the first intravitreal aflibercept injection. One and two months later, the several injections were applied.

Three months after the treatment initiation, significant improvement was observed. Patient’s new BCVA was 5/10, while ICGA demonstrated total polyp regression (Fig. 5a). In OCT RPE detachment was present, whereas subretinal fluid was not evident (Fig. 5b).

Thirteen months since the beginning of the treatment, the patient was re-examined. ODMC remained stable, her BCVA rose to 7/10, no polyps were detected,
Fig. 1 Fundus photography (a) and fluorescein angiography (b) of the left eye at baseline examination. a A deeply pigmented lesion, covering partially the optic nerve head and extending temporal into the peripapillary retina and choroid is consistent with optic disk melanocytoma (ODMC). Note the hard exudates temporal to ODMC and the pigmented spicules along the vessels. b Fluorescein angiography demonstrated diffuse blocked hypofluorescence in the area covered by ODMC, with diffuse hyperfluorescence at its temporal rim.

Fig. 2 ICGA (a) and OCT (b) examination of the left eye at baseline. a Three hyperfluorescent polypoidal lesions (white arrows) arising from the choroidal circulation were identified. b In OCT, the ODMC was shown as a gradually sloped nodular elevation, with hyperreflective anterior surface and dense posterior shadowing (black arrow). Subretinal fluid (white *), RPE detachment (white arrow-head), and a round protrusion beneath the posterior surface of the detached RPE (white arrow-head) were also detected at the region corresponding to polyps in ICGA.
while total resolution of RPE detachment was achieved (Fig. 6).

Discussion
This is the first report in literature presenting a rare clinical case of ODMC coexisting with PCV, in which the applied treatment and its clinical outcomes are described, and the findings of SPECTRALIS OCT, which depicts the clinical lesions with more accuracy, are provided.

Several therapeutic strategies have been applied in PCV treatment. PDT has been proven to be effective in inducing polyps occlusion and reducing exudative phenomena in PCV eyes, improving thus visual acuity [13–15]. However, an elevated risk of subretinal or sub-RPE hemorrhage exists, because PDT is usually guided both on the polyps and the surrounding network [14–16]. Based on previous reports, according to which PDT has no or little effect on the branching vascular network [17], we targeted the diode laser spot only on the polyps, avoiding thus the aforementioned adverse effects. Rouvas et al. [8] demonstrated that PDT alone was superior to intravitreal ranibizumab (IVR) injections combined or not with PDT, in achieving better functional and anatomical features over a 12 months period. The EVEREST II study suggested that PDT in combination with IVR injections, is superior compared to IVR monotherapy in achieving complete polyps regression.
and significant visual gains in PCV patients over a 12 months period [13].

Aflibercept is a recombinant fusion protein, binding to all isomers of vascular endothelial growth factor (VEGF)-A family, to VEGF-B and to placental growth factor [18, 19]. Its efficacy in resolving the polyps seems to be theoretically greater than ranibizumab, because the last one binds only to VEGF-A and has decreased binding affinity for VEGF compared to aflibercept [18, 19]. Furthermore, it has been suggested that aflibercept is more effective in visual improvement compared to ranibizumab for sub-RPE lesions [20]. The PLANET study [21] and Yamamoto et al. [22] showed that intravitreal aflibercept injections as monotherapy resulted in excellent visual and structural benefits, while Morimoto et al. [23] demonstrated that a treat-and-extend regimen with intravitreal aflibercept injections may be efficient for improvement of visual acuity and exudative phenomena in PCV eyes.

Our treatment strategy, consisting of PDT along with three intravitreal aflibercept injections, seems to be effective, since our patient experienced significant vision and anatomical gains. Polyps closed completely, their recurrence was prevented in a thirteen-month period, while resolution of RPE detachment occurred.

As for ODMC, no changes were detected during the 12-month follow up. ODMC is regarded to be a benign and stable lesion, while only 1–2% of the cases undergo a malignant transformation [3]. In the literature, no adverse effects of PDT on ODMC have been reported [24].

Conclusions
To the best of our knowledge, no previously published data describe a case of PCV coexisting with ODMC, displaying both ICGA and OCT findings. Furthermore, this is also the first report in literature that any form of treatment is applied for PCV associated with ODMC. Last but not least, we present the combination of PDT and intravitreal aflibercept injections as a promising treatment for PCV.

Abbreviations
BCVA: Best corrected visual acuity; FA: Fluorescein angiography; ICGA: Indocyanine green angiography; IVR: Intravitreal ranibizumab; OCT: Optical coherence tomography; OD: Right eye; ODMC: Optic disc melanocytoma; OS: Left eye; PCV: Polypoidal choroidal vasculopathy; PDT: Photodynamic therapy; RPE: Retinal pigment epithelium; VEGF: Vascular endothelial growth factor

Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

Authors’ contributions
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published. NSG participated in writing the case report. AR, MMM and PT examined the patient. AR performed the PDT and anti-VEGF treatment and helped draft the manuscript.

Ethics approval and consent to participate
The patient involved was provided a written informed consent in accordance with the tenets of the Declaration of Helsinki to having their medical data used for research purposes.

Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the editor of this journal.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Author details
1. 2nd Department of Ophthalmology, University of Athens Medical School, 'Attikon' General Hospital Athens, 1 Rimini Str, Haidari, 12462 Athens, Greece.
2. 1st Department of Ophthalmology, University of Athens Medical School, 'G. Genimmatas' General Hospital Athens, 154 Mesogion Avenue, Holargos, Athens, Greece.

Received: 17 April 2018 Accepted: 23 September 2018
Published online: 12 October 2018

References
1. Lee E, Sanjay S. Optic disc melanocytoma report of 5 patients from Singapore with a review of the literature. Asia Pac J Ophthal (Phil). 2015;2:273–8.
2. Zimmerman LE, Garron LK. Melanocytoma of the optic disc. Int Ophthalmol Clin. 1962;2:431–40.
3. Shields JA, Demirci H, Mashayekhi A, Shields CL. Melanocytoma of optic disc in 115 cases: the 2004 Samuel Johnson memorial lecture, part 1. Ophthalmology. 2004;111:1739–46.
4. García-Arumí J, Salvador F, Corcostegui B, Mateo C. Polypoidal choroidal vasculopathy in a patient with melanocytoma of the optic disc. Retina. 1994;14:173–6.
5. Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (PCV). Retina. 1990;10:1–8.
6. Liu K, Lai TY, Ma L, Lai FH, Young AL, Brelen ME, Tang MO, Pang CP, Chen LJ. Ethnic differences in the association of SERPING1 with age-related macular degeneration and polypoidal choroidal vasculopathy. Sci Rep. 2015;5:9424.
7. Spaide RF, Yannuzzi LA, Sorenson J, Orlich DA. Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina. 1995;15:100–10.
8. Rouvas AA, Papakostas TD, Ntoufaki A, Douvali M, Vergados I, Ladas ID. Photodynamic therapy, ranibizumab, and ranibizumab with photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Retina. 2011;31:464–74.
9. Uyama M, Wada M, Nagai Y, et al. Polypoidal choroidal vasculopathy: natural history. Am J Ophthalmol. 2002;133:639–48.
10. Bartlett HM, Willoughby B, Mandava N. Polypoidal choroidal vasculopathy in a patient with melanocytoma of the optic nerve. Retina. 2001;21:396–9.
11. Nicolás El-Haddad M, Clement Fernández F, Pérez-Salvador E, Martín Reyes C. Polypoidal choroidal vasculopathy in a patient with a melanocytoma of the optic nerve. Arch Soc Esp Oftalmol. 2002;77:455–8.
12. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report. Arch Ophthalmol. 1999;117:1292–45.
13. Koh A, Lai TY, Takayashi K, Wong TY, Chen LJ, Ramaiviboonsuk P, Tan CS, Feller C, Margaron L, Lin TH, Lee WK. EVEREST II study group. Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial. JAMA Ophthalmol. 2017;135:1206–13.
14. Chan WM, Lam DS, Lai TY, Liu DT, Li KK, Yao Y, Wong TH. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. Ophthalmology. 2004;111:1576–84.
15. Gomi F, Ohji M, Sayanagi K, Sawa M, Sakaguchi H, Oshima Y, Ikuno Y, Tano Y. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology. 2008;115:141–6.
16. Hitami Y, Tsujikawa A, Otani A, Yodoi Y, Akiwada H, Mandai M, Yoshimura N. Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy. Retina. 2007;27:335–41.
17. Wakabayashi T, Gomi F, Sawa M, Tsujikawa M, Tano Y. Marked vascular changes of polypoidal choroidal vasculopathy after photodynamic therapy. Br J Ophthalmol. 2008;92:396–40.
18. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.
19. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QT, Ho AC, Ouga Y, Simader C, Jaffe GJ, Slakter JS, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Sowade O, Zeitz O, Norenb erg C, Sandbrink R, Heier JS. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121:193–201.
20. Rouvas A, Chatziralli I, Androu A, Mpougatsou P, Alonistiotis D, Douvali M, Kabanarou SA, Theodosiadis P. Ranibizumab versus aflibercept for the treatment of vascularized pigment epithelium detachment due to age-related macular degeneration. Int Ophthalmol. 2018. https://doi.org/10.1007/s10792-018-0833-2 [Epub ahead of print].
21. Mitchell P, Wong T, Chen S, Zhang E, Ishibashi T, Leal S. Intravitreal aflibercept in the treatment of polypoidal choroidal vasculopathy: the planet study. EURETINA. 2017. http://www.euretina.org/barcelona2017/programme/freepapers-details.asp?id=15363&day=0. Accessed 7-10 Sept 2017.
22. Yamamoto A, Okada AA, Kano M, Kozumi H, Saito M, Maruko I, Sekiyu T, Iida T. One-year results of intravitreal aflibercept for polypoidal choroidal vasculopathy. Ophthalmology. 2015;122:1866–72.
23. Morimoto M, Matsumoto H, Mimura K, Akiyama H. Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2017;255:1891–7.
24. Chalam KV, Gupta SK, Shah GV, Agarwal S. Successful management of melanocytoma-associated choroidal neovascularization with photodynamic therapy. Eur J Ophthalmol. 2006;16:776–8.